|
| Press Releases |
|
 |
|
| Friday, February 14, 2025 |
|
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
| more info >> |
|
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
| In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025"). more info >> |
|
| Friday, January 24, 2025 |
|
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
| more info >> |
|
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
| China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 more info >> |
|
| Thursday, January 9, 2025 |
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
| Monday, December 9, 2024 |
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
| China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
| China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
| Monday, December 2, 2024 |
|
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
| China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
| China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
珠宝双展匯聚逾82,000环球买家
Mar 9, 2025 13:51 HKT/SGT
|
|
|
珠寶雙展匯聚逾82,000環球買家
Mar 9, 2025 13:41 HKT/SGT
|
|
|
Twin jewellery shows attract over 82,000 global buyers
Mar 9, 2025 13:19 HKT/SGT
|
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Mar 8, 2025 19:40 HKT/SGT
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 8, 2025 19:20 HKT/SGT
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 21:26: JST
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 7, 2025 20:31: JST
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 20:26 HKT/SGT
|
|
|
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值
Mar 7, 2025 19:24 HKT/SGT
|
|
|
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值
Mar 7, 2025 19:16 HKT/SGT
|
|
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙
Mar 7, 2025 18:28 HKT/SGT
|
|
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙
Mar 7, 2025 18:10 HKT/SGT
|
|
|
東信營銷科技：中國AI營銷龍頭斬獲多模態雙備案 技術實力獲國家級認證
Mar 7, 2025 17:58 HKT/SGT
|
|
|
东信营销科技：中国AI营销龙头斩获多模态双备案 技术实力获国家级认证
Mar 7, 2025 17:20 HKT/SGT
|
|
|
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 7, 2025 16:24 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
